Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 9:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,033 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Concomitant treatment Clear all
Completed Early Phase 1 Interventional

Primary Breast Cancer Occurring Concomitant With Pregnancy

NCT00510367
View directory record Official record
Conditions
Breast Cancer, Pregnancy
Interventions
5-Fluorouracil, Cyclophosphamide, Doxorubicin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2020 · Synced Oct 26, 2026, 9:30 PM EDT
Withdrawn Phase 2 Interventional

Non-Viral TCR Gene Therapy

NCT04102436
View directory record Official record
Conditions
Endocrine/Neuroendocrine, Non-Small Cell Lung Cancer, Breast Cancer, Gastrointestinal/Genitourinary Cancers, Ovarian Cancer
Interventions
Fludarabine, Cyclophosphamide, Aldesleukin, Sleeping Beauty Transposed PBL
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 26, 2026, 9:30 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day

NCT03234465
View directory record Official record
Conditions
Oral Mucositis
Interventions
AG013, Placebo
Biological · Other
Lead sponsor
Oragenics, Inc.
Industry
Eligibility
21 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
27
States / cities
Farmington, Connecticut • Newark, Delaware • Orlando, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 26, 2026, 9:30 PM EDT
Terminated Phase 2 Interventional Results available

Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma

NCT00808899
View directory record Official record
Conditions
Neuroblastoma
Interventions
Temsirolimus, Irinotecan, Surgical Resection of Primary Tumor, Cyclophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, PBSC, Radiation Therapy, 13-cis-retinoic acid
Drug · Procedure · Radiation
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 18 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression

NCT02422186
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (New Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
65 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
San Diego, California • New Haven, Connecticut • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Not applicable Interventional

The Effect of Cross-Education on Shoulder Arthroscopy

NCT04470570
View directory record Official record
Conditions
Rotator Cuff Tears, Rotator Cuff Injuries, Rotator Cuff Repair
Interventions
Cross-Education, Blood-Flow Restriction Training
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Phase 3 Interventional Results available

Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer

NCT01672892
View directory record Official record
Conditions
Cervical Cancer, Endometrial Cancer, Gastrointestinal Complications, Perioperative/Postoperative Complications, Radiation Toxicity, Urinary Complications, Urinary Tract Toxicity
Interventions
Standard radiation therapy, intensity-modulated radiation therapy
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
129
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 106 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 26, 2026, 9:30 PM EDT
Not yet recruiting Phase 2 Interventional

NAC-REPAIR for Post-surgical Pain

NCT07227649
View directory record Official record
Conditions
Carpal Tunnel Surgery, Trigger Finger Disorder, De Quervain Syndrome, Guyon's Canal, Dupuytren Contracture, Morton Neuroma, Tarsal Tunnel Syndrome, Plantar Fasciopathy, Peroneal Nerve Entrapment
Interventions
NAC, NAC 0mg/day (Placebo)
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Oct 26, 2026, 9:30 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer

NCT02571725
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
Interventions
Olaparib, Tremelimumab
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
5
States / cities
Tampa, Florida • Albuquerque, New Mexico • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 26, 2026, 9:30 PM EDT
Not listed Phase 3 Interventional

Safety and Effectiveness of Cortical Stimulation in the Treatment of Stroke Patients With Upper Extremity Hemiparesis

NCT00170716
View directory record Official record
Conditions
Stroke, Hemiparesis
Interventions
Cortical Stimulation and rehabilitation, Rehabilitation
Device · Other
Lead sponsor
Northstar Neuroscience
Industry
Eligibility
21 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
21
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Not applicable Interventional Results available

Home-based Therapeutic Drug Monitoring in Kidney Transplantation

NCT05005221
View directory record Official record
Conditions
Kidney Transplant
Interventions
Automated text messages
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 99 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Phase 3 Interventional Results available

AtriCure Bipolar Radiofrequency Ablation of Permanent Atrial Fibrillation

NCT00560885
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
AtriCure Bipolar System
Device
Lead sponsor
AtriCure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
9
States / cities
Sacramento, California • Indianapolis, Indiana • Grand Rapids, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Phase 3 Interventional

Concomitant Treatment of Permanent Atrial Fibrillation

NCT00566787
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System
Device
Lead sponsor
AtriCure, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
10
States / cities
Indianapolis, Indiana • Ann Arbor, Michigan • Grand Rapids, Michigan + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2012 · Synced Oct 26, 2026, 9:30 PM EDT
Active, not recruiting Not applicable Interventional

Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

NCT05478304
View directory record Official record
Conditions
Ischemic Stroke, Systemic Embolism
Interventions
AtriClip LAA Exclusion System
Device
Lead sponsor
AtriCure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6,573 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
102
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Jonesboro, Arkansas + 81 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 26, 2026, 9:30 PM EDT
Terminated Phase 1 Interventional

Phase I Study of HL-085 in Patients With Advanced Solid Tumors

NCT03976050
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
HL-085
Drug
Lead sponsor
Shanghai Kechow Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2020 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Phase 3 Interventional Results available

Long Term Evaluation of Sarilumab in Rheumatoid Arthritis Patients (SARIL-RA-EXTEND)

NCT01146652
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
SAR153191 (REGN88)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
2,023 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
75
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 66 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 26, 2026, 9:30 PM EDT
Withdrawn Phase 4 Interventional

Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.

NCT03640221
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus, Type 2
Interventions
Ertugliflozin, Hydrochlorothiazide 12.5mg, Microneurography, SKNA recordings, Static Handgrip, Post-handgrip forearm vascular occlusion, Testing of the Arterial Baroreflex Function
Drug · Device · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
35 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 26, 2026, 9:30 PM EDT
Withdrawn Not applicable Interventional

Phase I Study MR-guided SBRT to PCa

NCT03935308
View directory record Official record
Conditions
Low or Intermediate Risk Prostate Cancer
Interventions
MR guided Linear Accelerator
Radiation
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 25, 2022 · Synced Oct 26, 2026, 9:30 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine

NCT04856124
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Intranasal esketamine
Drug
Lead sponsor
Psych Atlanta
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mechanisms by Which Strength Training Ameliorates the Metabolic Syndrome

NCT00727779
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
strength training
Behavioral
Lead sponsor
East Tennessee State University
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Johnson City, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 26, 2026, 9:30 PM EDT
Recruiting Phase 2Phase 3 Interventional

Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery

NCT03051464
View directory record Official record
Conditions
Stage II Rectal Cancer, Organ Preservation, Non-operative Treatment, Rectal Cancer (Stage III), Rectal Cancer Patients
Interventions
Complete responders and Non-complete responders, Chemoradiation + EBRT Boost, Chemoradiation + HDRBT Boost
Procedure · Radiation
Lead sponsor
Sir Mortimer B. Davis - Jewish General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 26, 2026, 9:30 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis

NCT00489489
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide, Placebo (for Teriflunomide), Interferon-β
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 6, 2012 · Synced Oct 26, 2026, 9:30 PM EDT
Active, not recruiting Phase 2 Interventional

Photobiomodulation for the Prevention of Oral Mucositis

NCT07290413
View directory record Official record
Conditions
Oral Mucositis
Interventions
Photobiomodulation - INTRAORAL, Photobiomodulation - EXTRAORAL, Photobiomodulation - INTRAORAL and EXTRAORAL
Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
4 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 26, 2026, 9:30 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer

NCT05678010
View directory record Official record
Conditions
Solid Tumor, Metastatic Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Metastatic Tumor, Metastatic Cancer
Interventions
AZD1390, Stereotactic Body Radiotherapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
5
States / cities
Middletown, New Jersey • Commack, New York • Harrison, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 26, 2026, 9:30 PM EDT